Published in Antiviral Res on December 16, 2009
DRV/r + RPV QD: Efficacy and Toxicity Reduction | NCT01792570
Translational research in behavior analysis: historical traditions and imperative for the future. J Exp Anal Behav (2010) 2.65
Drug-induced oxidative stress and toxicity. J Toxicol (2012) 1.55
Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) (2011) 1.52
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One (2010) 1.48
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
Drug repositioning for personalized medicine. Genome Med (2012) 1.24
A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One (2011) 1.19
Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer (2012) 1.19
New insights into HIV assembly and trafficking. Physiology (Bethesda) (2011) 1.18
Patterns of resistance development with integrase inhibitors in HIV. Infect Drug Resist (2011) 1.17
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog (2010) 1.10
New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's Global Health Initiative (GHI). PLoS Negl Trop Dis (2011) 1.08
HIV type 1 Gag as a target for antiviral therapy. AIDS Res Hum Retroviruses (2011) 1.08
Different distribution of HIV-1 subtype and drug resistance were found among treatment naïve individuals in Henan, Guangxi, and Yunnan province of China. PLoS One (2013) 1.06
Clinical management of HIV drug resistance. Viruses (2011) 1.02
Latency reversal and viral clearance to cure HIV-1. Science (2016) 0.92
Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus. J Med Chem (2013) 0.92
Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92
Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert Opin Drug Metab Toxicol (2012) 0.91
Preoperative risk factors influencing the incidence of postoperative sepsis in human immunodeficiency virus-infected patients: a retrospective cohort study. World J Surg (2013) 0.91
Increasing access to oral health care for people living with HIV/AIDS in the U.S.: baseline evaluation results of the Innovations in Oral Health Care Initiative. Public Health Rep (2012) 0.90
Short communication: Transmitted HIV drug resistance in antiretroviral-naive pregnant women in north central Nigeria. AIDS Res Hum Retroviruses (2013) 0.89
Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PLoS One (2012) 0.89
Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther (2010) 0.89
A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa. AIDS Patient Care STDS (2015) 0.88
Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages. PLoS One (2011) 0.87
Treatment of postoperative infectious complications in patients with human immunodeficiency virus infection. World J Emerg Med (2014) 0.86
Tristetraprolin expression and microRNA-mediated regulation during simian immunodeficiency virus infection of the central nervous system. Mol Brain (2013) 0.86
Anti-infective treatment in HIV-infected patients during perioperative period. AIDS Res Ther (2012) 0.84
Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration. Antimicrob Agents Chemother (2013) 0.84
A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. PLoS One (2012) 0.83
Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol (2013) 0.83
Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role. J Acquir Immune Defic Syndr (2015) 0.82
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. PLoS One (2013) 0.82
The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study. Korean J Intern Med (2015) 0.82
Tautomerism provides a molecular explanation for the mutagenic properties of the anti-HIV nucleoside 5-aza-5,6-dihydro-2'-deoxycytidine. Proc Natl Acad Sci U S A (2014) 0.81
Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. Biomed Chromatogr (2011) 0.81
Targeted resequencing of HIV variants by microarray thermodynamics. Nucleic Acids Res (2013) 0.80
Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance. BMC Genomics (2013) 0.80
Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons. AIDS Res Hum Retroviruses (2011) 0.80
Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. J Infect Dis (2017) 0.79
Systems biology of HBOC-induced vasoconstriction. Curr Drug Discov Technol (2012) 0.79
Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds. Bioconjug Chem (2011) 0.79
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother (2012) 0.79
Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system. Antimicrob Agents Chemother (2011) 0.78
The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation. J Leukoc Biol (2012) 0.78
An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target. Antiviral Res (2016) 0.78
A rapid label-free method for quantitation of human immunodeficiency virus type-1 particles by nanospectroscopy. J Virol Methods (2012) 0.77
Prevention and treatment of surgical site infection in HIV-infected patients. BMC Infect Dis (2012) 0.76
Cellular imaging: a key phenotypic screening strategy for predictive toxicology. Front Pharmacol (2015) 0.76
Pokeweed antiviral protein alters splicing of HIV-1 RNAs, resulting in reduced virus production. RNA (2014) 0.76
Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson's Disease in a Patient with HIV Infection: Dual Clinical Benefit. Case Rep Neurol (2011) 0.76
Can Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa. AIDS Behav (2016) 0.76
The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget (2015) 0.76
Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. Nanomedicine (Lond) (2016) 0.75
Addressing viral resistance through vaccines. Future Virol (2015) 0.75
Resistance evolution in HIV - modeling when to intervene. Proc Am Control Conf (2012) 0.75
Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview. Front Microbiol (2016) 0.75
HIV psychiatry in the era of combined antiretroviral therapy: top five issues. J Int AIDS Soc (2015) 0.75
Molecular Events in Late Stages of HIV-1 Replication. JSM Microbiol (2013) 0.75
Disparities in HIV Clinical Outcomes among a Cohort of HIV-Infected Persons Receiving Care-Mississippi. Int J Environ Res Public Health (2017) 0.75
Vaccine nanoparticles for protection against HIV infection. Nanomedicine (Lond) (2017) 0.75
Perspectives on disclosure among children living with HIV in India. Child Youth Serv Rev (2016) 0.75
Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol (2012) 0.75
Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors. Mem Inst Oswaldo Cruz (2015) 0.75
From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany. BMC Public Health (2015) 0.75
Recent Insights into the HIV/AIDS Pandemic. Microb Cell (2016) 0.75
The Chinese herb-derived Sparstolonin B suppresses HIV-1 transcription. Virol J (2015) 0.75
Evaluation of the innate immune modulator acitretin as a strategy to clear the HIV reservoir. Antimicrob Agents Chemother (2017) 0.75
Probing Mercaptobenzamides as HIV Inactivators via Nucleocapsid Protein 7. ChemMedChem (2017) 0.75
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1994) 25.02
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 15.19
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science (1988) 13.46
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
The challenge of finding a cure for HIV infection. Science (2009) 8.41
AIDS as a zoonosis: scientific and public health implications. Science (2000) 8.28
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med (2008) 8.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol (1994) 6.76
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet (2008) 5.93
HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe (2008) 5.90
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Naturally acquired simian retrovirus infections in central African hunters. Lancet (2004) 5.34
Identification of human immunodeficiency virus sequences by using in vitro enzymatic amplification and oligomer cleavage detection. J Virol (1987) 5.27
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med (1970) 5.03
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 4.87
HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe (2009) 4.36
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Molecular targets for AIDS therapy. Science (1990) 4.28
The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol (2008) 4.27
AIDS: lessons learnt and myths dispelled. Lancet (2009) 4.03
Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells. Proc Natl Acad Sci U S A (2007) 3.99
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
The challenge of HIV-1 subtype diversity. N Engl J Med (2008) 3.88
Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California. MMWR Morb Mortal Wkly Rep (1981) 3.78
A new human immunodeficiency virus derived from gorillas. Nat Med (2009) 3.47
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet (1988) 3.37
The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA (2005) 3.14
Retracted Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature (2004) 3.12
Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis (2002) 2.98
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Strategies for antiviral therapy in AIDS. Nature (1987) 2.95
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92
Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol (2008) 2.83
Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature (2009) 2.78
Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet (1981) 2.75
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science (1984) 2.70
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med (1988) 2.68
Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst (2002) 2.38
Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet (1987) 2.30
The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One (2008) 2.23
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 2.21
Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov (2005) 2.14
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med (1988) 2.08
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res (2009) 2.07
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol (2004) 2.01
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A (1987) 1.96
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med (1987) 1.88
Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther (2004) 1.84
Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics (2002) 1.82
Promoter targeted small RNAs induce long-term transcriptional gene silencing in human cells. Nucleic Acids Res (2009) 1.79
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res (2009) 1.77
Adaptation of HIV-1 to its human host. Mol Biol Evol (2007) 1.77
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res (2009) 1.76
Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res (2009) 1.72
Synthesis and biological activity of several amino analogues of thymidine. J Med Chem (1978) 1.63
The impact of HIV and AIDS on Africa's economic development. BMJ (2002) 1.62
Latency: the hidden HIV-1 challenge. Retrovirology (2006) 1.59
Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1987) 1.57
Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing (2005) 1.57
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1986) 1.56
Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells. EMBO J (2009) 1.55
Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol (1981) 1.51
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem (2007) 1.51
Oligonucleotide-mediated retroviral RNase H activation leads to reduced HIV-1 titer in patient-derived plasma. AIDS (2009) 1.49
Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction. AIDS (1993) 1.48
Novel approaches to inhibiting HIV-1 replication. Antiviral Res (2009) 1.48
A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods (2007) 1.47
Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res (2009) 1.46
Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region. J Biol Chem (2008) 1.45
HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS (2009) 1.41
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers (2004) 1.37
HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr (1993) 1.36
Common themes in siRNA-mediated epigenetic silencing pathways. Int J Dev Biol (2009) 1.35
Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem (1988) 1.32
RNA-mediated transcriptional gene silencing in human cells. Curr Top Microbiol Immunol (2008) 1.32
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods (2006) 1.31
The discovery of HIV as the cause of AIDS. N Engl J Med (2003) 1.31
Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res (2009) 1.30
The origins of HIV and implications for the global epidemic. Curr Infect Dis Rep (2007) 1.29
Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. Proc Natl Acad Sci U S A (1974) 1.26
Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res (2006) 1.24
HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res (2009) 1.23
Epidemiology of human immunodeficiency virus in the United States. Clin Microbiol Rev (2007) 1.23